265 related articles for article (PubMed ID: 36272529)
21. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.
Maziarz RT; Yang H; Liu Q; Wang T; Zhao J; Lim S; Lee S; Dalal A; Bollu V
Leuk Lymphoma; 2022 Sep; 63(9):2052-2062. PubMed ID: 35422192
[TBL] [Abstract][Full Text] [Related]
22. Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Makita S; Yamamoto G; Maruyama D; Asano-Mori Y; Kaji D; Ananthakrishnan R; Ogasawara K; Stepan L; Schusterbauer C; Rettby N; Hasskarl J; Izutsu K
Cancer Med; 2022 Dec; 11(24):4889-4899. PubMed ID: 35619325
[TBL] [Abstract][Full Text] [Related]
23. Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma.
Ghanem B
Invest New Drugs; 2023 Oct; 41(5):710-718. PubMed ID: 37572232
[TBL] [Abstract][Full Text] [Related]
24. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma.
Oluwole OO; Jansen JP; Lin VW; Chan K; Keeping S; Navale L; Locke FL
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1581-1588. PubMed ID: 32561336
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
[TBL] [Abstract][Full Text] [Related]
26. Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.
Yamshon S; Gribbin C; Alhomoud M; Chokr N; Chen Z; Demetres M; Pasciolla M; Leonard J; Shore T; Martin P
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):e235-e256.e2. PubMed ID: 38582666
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach.
Kurte MS; Siefen AC; Jakobs F; von Tresckow B; Reinhardt HC; Kron F
Eur J Haematol; 2023 Dec; 111(6):895-908. PubMed ID: 37644352
[TBL] [Abstract][Full Text] [Related]
28. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Topp MS; van Meerten T; Houot R; Minnema MC; Bouabdallah K; Lugtenburg PJ; Thieblemont C; Wermke M; Song KW; Avivi I; Kuruvilla J; Dührsen U; Zheng Y; Vardhanabhuti S; Dong J; Bot A; Rossi JM; Plaks V; Sherman M; Kim JJ; Kerber A; Kersten MJ
Br J Haematol; 2021 Nov; 195(3):388-398. PubMed ID: 34590303
[TBL] [Abstract][Full Text] [Related]
29. Estimating the Cost per Clinical Outcome of Second-Line Liso-Cel Versus Autologous Stem Cell Transplantation in Patients with Transplantation-Intended Relapsed/Refractory Large B Cell Lymphoma.
Saeedian M; Badaracco J; Botros A; Gitlin M; Keating SJ
Transplant Cell Ther; 2023 Nov; 29(11):712.e1-712.e7. PubMed ID: 37544410
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.
Roth JA; Sullivan SD; Lin VW; Bansal A; Purdum AG; Navale L; Cheng P; Ramsey SD
J Med Econ; 2018 Dec; 21(12):1238-1245. PubMed ID: 30260711
[TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement.
Yi D; Gergis M; Elgohary G; Hsu J; Yang Y; Bi X; Gergis U
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):66-72. PubMed ID: 36537908
[TBL] [Abstract][Full Text] [Related]
32. Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma.
Dickinson M; Martinez-Lopez J; Jousseaume E; Yang H; Chai X; Xiang C; Wang T; Zhang J; Ramos R; Schuster SJ; Fowler N
Leuk Lymphoma; 2024 Mar; 65(3):323-332. PubMed ID: 38179688
[TBL] [Abstract][Full Text] [Related]
33. A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
Kuhnl A; Roddie C; Kirkwood AA; Tholouli E; Menne T; Patel A; Besley C; Chaganti S; Sanderson R; O'Reilly M; Norman J; Osborne W; Bloor A; Lugthart S; Malladi R; Patten PEM; Neill L; Martinez-Cibrian N; Kennedy H; Phillips EH; Jones C; Sharplin K; El-Sharkawi D; Latif AL; Mathew A; Uttenthal B; Stewart O; Marzolini MAV; Townsend W; Cwynarski K; Ardeshna K; Ardavan A; Robinson K; Pagliuca A; Collins GP; Johnson R; McMillan A
Br J Haematol; 2022 Aug; 198(3):492-502. PubMed ID: 35485402
[TBL] [Abstract][Full Text] [Related]
34. The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial.
Perales MA; Kuruvilla J; Snider JT; Vadgama S; Blissett R; El-Moustaid F; Smith NJ; Patel AR; Johnston PB
Transplant Cell Ther; 2022 Nov; 28(11):750.e1-750.e6. PubMed ID: 35970302
[TBL] [Abstract][Full Text] [Related]
35. Novel CAR T cell therapies for patients with large B cell lymphoma.
Goto H; Onozawa M; Teshima T
Int J Hematol; 2024 May; ():. PubMed ID: 38795249
[TBL] [Abstract][Full Text] [Related]
36. Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023.
Ryan CE; Jacobson CA
Semin Hematol; 2023 Nov; 60(5):322-328. PubMed ID: 38199906
[TBL] [Abstract][Full Text] [Related]
37. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
Nastoupil LJ; Jain MD; Feng L; Spiegel JY; Ghobadi A; Lin Y; Dahiya S; Lunning M; Lekakis L; Reagan P; Oluwole O; McGuirk J; Deol A; Sehgal AR; Goy A; Hill BT; Vu K; Andreadis C; Munoz J; Westin J; Chavez JC; Cashen A; Bennani NN; Rapoport AP; Vose JM; Miklos DB; Neelapu SS; Locke FL
J Clin Oncol; 2020 Sep; 38(27):3119-3128. PubMed ID: 32401634
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review.
Wu X; Zhang X; Xun R; Liu M; Sun Z; Huang J
Front Immunol; 2021; 12():693200. PubMed ID: 34290712
[TBL] [Abstract][Full Text] [Related]
39. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Halford Z; Anderson MK; Bennett LL
Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
[TBL] [Abstract][Full Text] [Related]
40. Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison.
Schuster SJ; Zhang J; Yang H; Agarwal A; Tang W; Martinez-Prieto M; Bollu V; Kuzan D; Maziarz RT; Kersten MJ
Leuk Lymphoma; 2022 Apr; 63(4):845-854. PubMed ID: 34978255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]